Pediatric Growth Hormone Deficiency PGHD Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight | Key Companies- Pfizer, Opko health, and Several Others

June 27 20:30 2022
Pediatric Growth Hormone Deficiency PGHD Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight | Key Companies- Pfizer, Opko health, and Several Others

DelveInsight’s Pediatric Growth Hormone Deficiency PGHD Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Pediatric Growth Hormone Deficiency Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).


Pediatric Growth Hormone Deficiency PGHD: An Overview

Pediatric Growth Hormone Deficiency (PGHD) occurs when the pituitary gland does not make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired). The child is more at risk for GH deficiency if they have any of these like brain injury, brain tumor, and radiation treatment to the head. To diagnose the GH deficiency, the healthcare providers need to check for conditions such as normal variations of growth, such as familial short stature; other disorders, such as thyroid hormone deficiency or kidney disease, and genetic conditions.

The tests like blood tests, X-rays, CT scans, and MRI. Treatment is mainly done with daily injections of synthetic growth hormone, results are often seen as soon as 3-4 months after treatment starts. The treatment can last several years until late puberty when growing is finished.


Download Free Sample Report Now @


Some of the key highlights of the Pediatric Growth Hormone Deficiency PGHD Market Report

  • As per the study by Bonfig Walter et al. the Growth Hormone Deficiency prevalence ranges between 1:3500 and 1:8700 in Germany.
  • According to Boston’s Children’s Hospital, about one in 4,000 to 10,000 children have a growth hormone deficiency.
  • According to Brod Meryl et al., the prevalence of childhood Growth Hormone Deficiency reported in published studies is within the range of 1.8–2.9 per 10,000 in Europe.
  • According to the NORD, Growth hormone deficiency affects males and females equally. However, given the greater concern for boys with short stature in most societies, diagnosis tends to favor males over females. About 73% of patients with idiopathic GHD in the NCGS were male. Additionally, patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male.


Pediatric Growth Hormone Deficiency PGHD Market

Pediatric Growth Hormone Deficiency PGHD Market Size is anticipated to increase in the coming years owing to the increasing prevalent population and expected entry of long-acting hGH emerging therapies for PGHD treatment in the 7MM.

Of the emerging therapies, the most anticipated product to get launched in the market includes TransCon hGH, Somapacitan, Somatrogon, LUM-201, and others. These therapies are expected to change the Growth Hormone Deficiency market dynamics in the upcoming years. Some of the Growth Hormone Deficiency therapies also got Orphan designation.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Pediatric Growth Hormone Deficiency market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Pediatric Growth Hormone Deficiency market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.


Pediatric Growth Hormone Deficiency Epidemiology

The epidemiology section covers insights into the historical and current Pediatric Growth Hormone Deficiency patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Pediatric Growth Hormone Deficiency PGHD Epidemiology Segmentation

  • Total Prevalent Pool
  • Total Prevalent Patient Pool
  • Diagnosed Patient Pool
  • Treated Patient Pool


Pediatric Growth Hormone Deficiency Therapeutics Analysis

The available therapeutic treatment options in the Pediatric Growth Hormone Deficiency (PGHD) landscape aims for long-term efficacy. As per DelveInsight, Pediatric Growth Hormone Deficiency (PGHD) market dynamics is anticipated to change in the coming years owing to the improvement in healthcare spending across the world.


Pediatric Growth Hormone Deficiency PGHD Market Companies include:

  • Pfizer
  • Opko health
  • Novo Nordisk
  • Ascendis Pharma
  • Lumos Pharma, and Several Others


Pediatric Growth Hormone Deficiency PGHD Drugs include:

  • LUM-201
  • TransCon hGH
  • Somapacitan
  • Somatrogon, and Several Others


The pipeline for Pediatric Growth Hormone Deficiency (PGHD) is full of long-acting hGH as it is the major unmet need of this indication. On the other hand, the current pipeline is robust with late-stage products and will change the dynamics of the upcoming market. 


Get More Detailed Insights Into the Emerging Therapies & Key Companies –


Table of Content

  1. Key Insights
  2. Executive Summary
  3. Competitive Intelligence Analysis
  4. Market Overview at a Glance
  5. Disease Background and Overview
  6. Patient Journey
  7. Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Pediatric Growth Hormone Deficiency (PGHD) Treatment
  11. Marketed Products
  12. Emerging Therapies
  13. Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight


Get in touch with our Business Expert @


About Us

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States